Apolipoprotein A-I and risk for cardiovascular diseases
Standard
Apolipoprotein A-I and risk for cardiovascular diseases. / Khuseyinova, Natalie; Koenig, Wolfgang.
in: CURR ATHEROSCLER REP, Jahrgang 8, Nr. 5, 09.2006, S. 365-373.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Apolipoprotein A-I and risk for cardiovascular diseases
AU - Khuseyinova, Natalie
AU - Koenig, Wolfgang
PY - 2006/9
Y1 - 2006/9
N2 - Increased concentrations of high-density lipoprotein (HDL) cholesterol have been closely associated with decreased risk of future cardiovascular disease. This protective effect of HDL has been mainly attributed to its involvement in reverse cholesterol transport. More recently, it has been suggested that apolipoprotein A-I (apoA-I), the major protein component of HDL, possesses nearly identical information as HDL in terms of risk prediction for future cardiovascular disease. This makes apoA-I a very attractive biomarker candidate for implementation into clinical practice, taking into account its analytical advantages. This review summarizes our current knowledge based on observations from recent studies, with emphasis on potential pathophysiologic mechanisms of action and on the clinical utility of apoA-I as a predictor of cardiovascular risk.
AB - Increased concentrations of high-density lipoprotein (HDL) cholesterol have been closely associated with decreased risk of future cardiovascular disease. This protective effect of HDL has been mainly attributed to its involvement in reverse cholesterol transport. More recently, it has been suggested that apolipoprotein A-I (apoA-I), the major protein component of HDL, possesses nearly identical information as HDL in terms of risk prediction for future cardiovascular disease. This makes apoA-I a very attractive biomarker candidate for implementation into clinical practice, taking into account its analytical advantages. This review summarizes our current knowledge based on observations from recent studies, with emphasis on potential pathophysiologic mechanisms of action and on the clinical utility of apoA-I as a predictor of cardiovascular risk.
KW - Apolipoprotein A-I/blood
KW - Cardiovascular Diseases/blood
KW - Humans
KW - Prognosis
KW - Risk Factors
U2 - 10.1007/s11883-006-0033-9
DO - 10.1007/s11883-006-0033-9
M3 - SCORING: Review article
C2 - 16901406
VL - 8
SP - 365
EP - 373
JO - CURR ATHEROSCLER REP
JF - CURR ATHEROSCLER REP
SN - 1523-3804
IS - 5
ER -